Brady Todd C 4
4 · Aldeyra Therapeutics, Inc. · Filed Sep 11, 2023
Insider Transaction Report
Form 4
Brady Todd C
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2023-09-07$0.55/sh+192,084$106,030→ 1,647,369 total - Exercise/Conversion
Stock Option (right to buy)
2023-09-07−32,953→ 0 totalExercise: $0.55Exp: 2023-09-07→ Common Stock (32,953 underlying) - Exercise/Conversion
Common Stock
2023-09-07$0.55/sh+48,021$26,508→ 1,728,343 total - Exercise/Conversion
Stock Option (right to buy)
2023-09-07−192,084→ 0 totalExercise: $0.55Exp: 2023-09-07→ Common Stock (192,084 underlying) - Exercise/Conversion
Stock Option (right to buy)
2023-09-07−48,021→ 0 totalExercise: $0.55Exp: 2023-09-07→ Common Stock (48,021 underlying) - Exercise/Conversion
Common Stock
2023-09-07$0.55/sh+32,953$18,190→ 1,680,322 total - Tax Payment
Common Stock
2023-09-07$7.22/sh−73,807$532,887→ 1,654,536 total
Footnotes (2)
- [F1]Represents the number of shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the exercise of the stock options.
- [F2]The stock option is fully vested.